While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products,  advocacy and trade groups anticipate sunscreen ingredient testing will be one discussion topic. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.

Recalls include one lot of CVS Health Sinus Relief manufactured by Product Quest Manufacturing, Walmart's Equate laxative made by Lupin's US office and 12 cough and cold products marketed under Preferred Plus Pharmacy and other private label brands and made by RIJ Pharmaceutical Corp. Chart provides update on recent US OTC recalls.

"We're investing more to drive growth as we allocate capital to support the launches of new products in the segment like Lumify, for DTC advertising that continue to drive sales growth of other US consumer products like our eye vitamins," says CEO Joseph Papa.

Submitting an OTC switch of Nasonex would be a first for Perrigo, as would marketing a national brand OTC if the switch is approved. In tandem with announcing divesture of Perrigo's Rx business, CEO Uwe Rohrhoff says marketing national brands in some OTC categories fits in the company's "value-creation road map."

Proprietary Association of Great Britain urges UK and EU to “ensure appropriate mutual recognition agreements are in place” following UK's Brexit withdrawal, says chief executive John Smith.

House and Senate appropriators' take note that US FDA has not approved an additional OTC sunscreen ingredient since the 2014 passage of the Sunscreen Innovation Act.